雅視光學(01120.HK)擬1120萬元收購五彩司徠柏光學科技(江蘇)10%股權
格隆匯6月10日丨雅視光學(01120.HK)宣佈,於2025年6月10日,買方雅視光學科技(深圳)(公司間接全資附屬公司)與賣方訂立股權轉讓協議,據此,買方同意收購而賣方同意出售目標公司五彩司徠柏光學科技(江蘇)有限公司合共10%股權,總代價爲人民幣1120萬元。
交易完成後,買方將擁有目標公司合共65%的股權,賣方將擁有目標公司35%的股權。
目標公司爲一間於中國成立之有限公司。目標公司主要從事光學眼鏡片的設計、製造及銷售。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.